Aplastic Anemia - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/05/15
頁 數：54頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Aplastic Anemia - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Aplastic Anemia - Pipeline Review, H1 2014’, provides an overview of the Aplastic Anemia’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Aplastic Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Aplastic Anemia and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Aplastic Anemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Aplastic Anemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Aplastic Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Aplastic Anemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Aplastic Anemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Aplastic Anemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Aplastic Anemia - Pipeline Review, H1 2014’, provides an overview of the Aplastic Anemia’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Aplastic Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Aplastic Anemia and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Aplastic Anemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Aplastic Anemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Aplastic Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Aplastic Anemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Aplastic Anemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Aplastic Anemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Aplastic Anemia Overview 6
Therapeutics Development 7
Pipeline Products for Aplastic Anemia - Overview 7
Pipeline Products for Aplastic Anemia - Comparative Analysis 8
Aplastic Anemia - Therapeutics under Development by Companies 9
Aplastic Anemia - Therapeutics under Investigation by Universities/Institutes 10
Aplastic Anemia - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Aplastic Anemia - Products under Development by Companies 14
Aplastic Anemia - Products under Investigation by Universities/Institutes 15
Aplastic Anemia - Companies Involved in Therapeutics Development 16
Amgen Inc. 16
GlaxoSmithKline plc 17
Bio-Matrix Scientific Group, Inc. 18
Pluristem Therapeutics Inc. 19
Aprogen, Inc. 20
Aplastic Anemia - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
eltrombopag olamine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
romiplostim - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
PLX Cells for Aplastic Anemia - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
HemaXellerate - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
darbepoetin alfa biosimilar - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Immunotoxins - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Aplastic Anemia - Recent Pipeline Updates 39
Aplastic Anemia - Dormant Projects 46
Aplastic Anemia - Discontinued Products 47
Aplastic Anemia - Product Development Milestones 48
Featured News & Press Releases 48
Feb 28, 2014: Ligand Partner GlaxoSmithKline Submits U.S. Regulatory Application for Promacta (eltrombopag) for Severe Aplastic Anaemia 48
Feb 03, 2014: GSK gains FDA Breakthrough Therapy designation for Promacta/Revolade for severe aplastic anaemia 48
Feb 03, 2014: Ligand Partner GlaxoSmithKline Gains FDA Breakthrough Therapy Designation for Promacta/Revolade for Severe Aplastic Anemia 48
Dec 11, 2013: Regen BioPharma Announces HemaXellerate I Efficacy Data in Animal Model of Aplastic Anemia 49
Sep 27, 2013: Bio-Matrix Scientific Group's Subsidiary Regen BioPharma Enters Into Preclinical Trials Agreement for HemaXellerate I Covering Aplastic Anemia 49
Jun 20, 2013: Pluristem Therapeutics Announces Publication Of Preclinical Results Of PLX-RAD Cells In Journal PLOS ONE 50
Jun 07, 2013: Regen BioPharma Submits Responses To FDA Comments Regarding HemaXellerate Clinical Program 51
Apr 05, 2013: Regen BioPharma Files IND Application With FDA On HemaXellerate I Stem Cell Drug For Aplastic Anemia 51
Mar 18, 2013: Regen BioPharma Receives IND Number From FDA For HemaXellerate 52
Feb 21, 2013: Pluristem Receives FDA Orphan Drug Status Designation For Treatment Of Aplastic Anemia 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54
List of Tables
Number of Products under Development for Aplastic Anemia, H1 2014 7
Number of Products under Development for Aplastic Anemia - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Aplastic Anemia - Pipeline by Amgen Inc., H1 2014 16
Aplastic Anemia - Pipeline by GlaxoSmithKline plc, H1 2014 17
Aplastic Anemia - Pipeline by Bio-Matrix Scientific Group, Inc., H1 2014 18
Aplastic Anemia - Pipeline by Pluristem Therapeutics Inc., H1 2014 19
Aplastic Anemia - Pipeline by Aprogen, Inc., H1 2014 20
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Stage and Target, H1 2014 23
Number of Products by Stage and Mechanism of Action, H1 2014 25
Number of Products by Stage and Route of Administration, H1 2014 27
Number of Products by Stage and Molecule Type, H1 2014 29
Aplastic Anemia Therapeutics - Recent Pipeline Updates, H1 2014 39
Aplastic Anemia - Dormant Projects, H1 2014 46
Aplastic Anemia - Discontinued Products, H1 2014 47
List of Figures
Number of Products under Development for Aplastic Anemia, H1 2014 7
Number of Products under Development for Aplastic Anemia - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Products, H1 2014 13
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Top 10 Target, H1 2014 22
Number of Products by Stage and Top 10 Target, H1 2014 23
Number of Products by Top 10 Mechanism of Action, H1 2014 24
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 25
Number of Products by Top 10 Route of Administration, H1 2014 26
Number of Products by Stage and Top 10 Route of Administration, H1 2014 27
Number of Products by Top 10 Molecule Type, H1 2014 28
Number of Products by Stage and Top 10 Molecule Type, H1 2014 29
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Aplastic Anemia Overview 6
Therapeutics Development 7
Pipeline Products for Aplastic Anemia - Overview 7
Pipeline Products for Aplastic Anemia - Comparative Analysis 8
Aplastic Anemia - Therapeutics under Development by Companies 9
Aplastic Anemia - Therapeutics under Investigation by Universities/Institutes 10
Aplastic Anemia - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Aplastic Anemia - Products under Development by Companies 14
Aplastic Anemia - Products under Investigation by Universities/Institutes 15
Aplastic Anemia - Companies Involved in Therapeutics Development 16
Amgen Inc. 16
GlaxoSmithKline plc 17
Bio-Matrix Scientific Group, Inc. 18
Pluristem Therapeutics Inc. 19
Aprogen, Inc. 20
Aplastic Anemia - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
eltrombopag olamine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
romiplostim - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
PLX Cells for Aplastic Anemia - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
HemaXellerate - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
darbepoetin alfa biosimilar - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Immunotoxins - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Aplastic Anemia - Recent Pipeline Updates 39
Aplastic Anemia - Dormant Projects 46
Aplastic Anemia - Discontinued Products 47
Aplastic Anemia - Product Development Milestones 48
Featured News & Press Releases 48
Feb 28, 2014: Ligand Partner GlaxoSmithKline Submits U.S. Regulatory Application for Promacta (eltrombopag) for Severe Aplastic Anaemia 48
Feb 03, 2014: GSK gains FDA Breakthrough Therapy designation for Promacta/Revolade for severe aplastic anaemia 48
Feb 03, 2014: Ligand Partner GlaxoSmithKline Gains FDA Breakthrough Therapy Designation for Promacta/Revolade for Severe Aplastic Anemia 48
Dec 11, 2013: Regen BioPharma Announces HemaXellerate I Efficacy Data in Animal Model of Aplastic Anemia 49
Sep 27, 2013: Bio-Matrix Scientific Group's Subsidiary Regen BioPharma Enters Into Preclinical Trials Agreement for HemaXellerate I Covering Aplastic Anemia 49
Jun 20, 2013: Pluristem Therapeutics Announces Publication Of Preclinical Results Of PLX-RAD Cells In Journal PLOS ONE 50
Jun 07, 2013: Regen BioPharma Submits Responses To FDA Comments Regarding HemaXellerate Clinical Program 51
Apr 05, 2013: Regen BioPharma Files IND Application With FDA On HemaXellerate I Stem Cell Drug For Aplastic Anemia 51
Mar 18, 2013: Regen BioPharma Receives IND Number From FDA For HemaXellerate 52
Feb 21, 2013: Pluristem Receives FDA Orphan Drug Status Designation For Treatment Of Aplastic Anemia 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54
List of Tables
Number of Products under Development for Aplastic Anemia, H1 2014 7
Number of Products under Development for Aplastic Anemia - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Aplastic Anemia - Pipeline by Amgen Inc., H1 2014 16
Aplastic Anemia - Pipeline by GlaxoSmithKline plc, H1 2014 17
Aplastic Anemia - Pipeline by Bio-Matrix Scientific Group, Inc., H1 2014 18
Aplastic Anemia - Pipeline by Pluristem Therapeutics Inc., H1 2014 19
Aplastic Anemia - Pipeline by Aprogen, Inc., H1 2014 20
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Stage and Target, H1 2014 23
Number of Products by Stage and Mechanism of Action, H1 2014 25
Number of Products by Stage and Route of Administration, H1 2014 27
Number of Products by Stage and Molecule Type, H1 2014 29
Aplastic Anemia Therapeutics - Recent Pipeline Updates, H1 2014 39
Aplastic Anemia - Dormant Projects, H1 2014 46
Aplastic Anemia - Discontinued Products, H1 2014 47
List of Figures
Number of Products under Development for Aplastic Anemia, H1 2014 7
Number of Products under Development for Aplastic Anemia - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Products, H1 2014 13
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Top 10 Target, H1 2014 22
Number of Products by Stage and Top 10 Target, H1 2014 23
Number of Products by Top 10 Mechanism of Action, H1 2014 24
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 25
Number of Products by Top 10 Route of Administration, H1 2014 26
Number of Products by Stage and Top 10 Route of Administration, H1 2014 27
Number of Products by Top 10 Molecule Type, H1 2014 28
Number of Products by Stage and Top 10 Molecule Type, H1 2014 29
